Also trades as: MDP.TO (TSX) · $vol 0M
MEDXF OTC
Medexus Pharmaceuticals Inc.
1W: -8.0%
1M: -12.6%
3M: -7.2%
YTD: +49.1%
1Y: +80.5%
3Y: +50.5%
5Y: +38.6%
$3.34
-0.11 (-3.22%)
Weekly Expected Move ±3.8%
$3
$3
$3
$3
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$99M
-8.3% ▼
5Y CAGR: +4.5%
Gross Profit
$54M
-3.8% ▼
5Y CAGR: +5.3%
Operating Income
$6M
-29.0% ▼
Net Income
-$2M
-206.5% ▼
EPS (Diluted)
$-0.07
-185.5% ▼
EBITDA
$13M
-24.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $77M | $108M | $113M | $108M | $99M |
| YoY Growth | -3.7% | +40.9% | +4.6% | -4.2% | -8.3% |
| Cost of Revenue | $39M | $48M | $54M | $52M | $45M |
| Gross Profit | $38M | $60M | $60M | $57M | $54M |
| Gross Margin | 49.4% | 55.5% | 52.6% | 52.2% | 54.8% |
| R&D Expenses | $6M | $3M | $8M | $8M | $9M |
| SG&A Expenses | $44M | $48M | $38M | $36M | $39M |
| Operating Expenses | $50M | $52M | $49M | $48M | $49M |
| Operating Income | -$15M | $8M | $11M | $8M | $6M |
| Operating Margin | -19.6% | 7.0% | 9.5% | 7.6% | 5.9% |
| Interest Expense | $12M | $14M | $13M | $8M | $5M |
| Income Before Tax | -$4M | -$5M | $106K | $1M | -$2M |
| Tax Expense | -$941K | -$6M | $320K | -$807K | $120K |
| Net Income | -$3M | $1M | -$214K | $2M | -$2M |
| Net Margin | -3.8% | 1.1% | -0.2% | 2.1% | -2.4% |
| EPS (Diluted) | $-0.14 | $0.06 | $-0.01 | $0.08 | $-0.07 |
| EBITDA | $15M | $15M | $19M | $17M | $13M |
| Shares Outstanding | 20M | 21M | 22M | 27M | 32M |